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Introduction
Homeopathy is a system of medicine that uses specific preparations of substances whose effects, when administered to healthy subjects, correspond to the manifestations of the disorder (symptoms, clinical signs, pathological states) in the individual patient. 1 In individualised homeopathy-as originally defined by its founder, Samuel Hahnemann-typically a single homeopathic medicine is selected on the basis of the 'symptom picture' of a patient. In clinical homeopathy, by contrast, one or more homeopathic medicines are administered for standard clinical situations or conventional diagnoses. In complex homeopathy, several homeopathic medicines are combined in a fixed ('complex') formulation. Isopathy is the use of homeopathic dilutions from the causative agent of the disease itself, or from a product of the disease process, to treat the condition. 1 In the context of a randomised controlled trial (RCT), none of the latter three approaches involves matching a patient with the 'total symptom picture' of an individually prescribed homeopathic medicine: each is thus termed non-individualised homeopathy.
The current systematic review (SR) focuses on RCTs of non-individualised homeopathic treatment (NIHT), in which the control (comparator) group was something other than placebo (OTP). Two essentially different options exist for OTP study design of RCTs: (1) other therapeutic intervention (e.g. a conventional medicine or a physical therapy), which can be sub-divided into (a) trials in which NIHT is given as an alternative to the comparator intervention, and (b) trials in which NIHT combined with the other intervention is compared with the other intervention alone (the '[A þ B] versus B' approach); (2) no therapeutic intervention (usually waiting-list controls). Trials of type 1 can be regarded as 'comparative effectiveness' studies. We have previously conducted an SR of OTP-controlled RCTs of individualised homeopathy, 2 as well as two SRs of placebo-controlled RCTs of homeopathy.
3,4
No previous SR has considered solely RCTs of non-individualised homeopathy that were controlled by an OTP intervention. One SR of OTP-controlled trials did focus on individualised homeopathy:
5 published in 1999, it identified six eligible trials, two of which favoured homeopathy, two favoured conventional drugs, and two were non-conclusive. That review concluded overall that the 'value of individualized homoeopathy relative to allopathic treatments' was not known. An OTP-controlled trial would usually be intended to possess a 'pragmatic' rather than an 'explanatory' study attitude. 6 A pragmatic trial tends to promote external validity (generalisability of results to a relevant population of patients). 7, 8 Though it is seldom formally approached by trialists or in SRs, 6, 9 external validity can be addressed in a tool (PRECIS), developed by Thorpe et al in 2009 , that assesses a trial design's positioning on 'the pragmatic-explanatory continuum'. 10 For the current SR of OTP-controlled trials of NIHT, we assess each study's internal validity as well as its external validity, with a view to appraising both its intrinsic quality and the extent of its pragmatic/explanatory attitude.
Aim of the Study
Our objective was to examine comparative effectiveness of NIHT in OTP-controlled trials of any clinical condition, in adults or children, for which there was at least one eligible RCT. Using meta-analysis, we aimed to evaluate RCTs that have investigated NIHT: (study design 1a) in comparison to another therapeutic intervention; (study design 1b) adjunctively with another treatment intervention, in comparison to that other intervention alone ('[A þ B] versus B'); or (study design 2) compared with no other intervention. RCTs were further sub-categorised as superiority trials or equivalence/ non-inferiority trials. An additional aim was, if possible, to evaluate by meta-analysis the comparative effectiveness of NIHT for any given clinical condition or category of conditions. In all cases, we reflected matters of internal validity (risk of bias) and external validity (pragmatic/explanatory study attitude).
Methods
Methods complied fully with the PRISMA 2009 checklist (►Supplementary File 1 [online only]) and with our published study protocol.
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Search Strategy, Data Sources and Trial Eligibility
We conducted a systematic literature search to identify RCTs that compared NIHT with something other than placebo, for any clinical condition. 12 Each of the following electronic databases was searched from its inception up to the end of 2011, with updated searches of the same databases up to the end of 2016: AMED; CAM-Quest; CINAHL; Cochrane Central Register of Controlled Trials; Embase; Hom-Inform; LILACS; PubMed; Science Citation Index; Scopus. For the update, CORE-Hom was also searched, using the term 'randomised' or 'unknown' in the Sequence Generation field. The full electronic search strategy for PubMed (Cochrane Highly Sensitive Search Strategy) was conducted as per the above: '((homeopath Ã or homoeopath Specific pre-defined exclusion criteria were then applied:
• Trials of homeopathic prophylaxis • Trials with crossover design • Research using radionically prepared 'homeopathic' medicines
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• The tested intervention is NIHT in tandem with other (complementary or conventional) medicine or therapy, and where the nature of the combined comparator intervention makes it impossible to distinguish any effects due to NIHT a
• Other specified reason.
Whereas a placebo-controlled trial of non-individualised homeopathy can be fully blinded, it is more difficult-and sometimes impossible-to achieve such blinding in a corresponding OTP-controlled trial. Unlike the case for our corresponding SR of placebo-controlled trials, 4 therefore, patientand/or practitioner-unblinded trials are eligible for the current SR of OTP trials. Only published data were eligible for analysis. The authors of eligible articles were not approached for clarification on unclear or missing facts;
14 however, original authors' crossreference to their previously published study methods were followed up and taken into account as necessary. For trials with more than two study groups, and where such trials had not previously been catalogued under 'placebo-controlled', only the data concerning comparisons between NIHT and OTP were extracted from the articles; in relevant cases of more than one OTP control, a study group comprising actual treatment was favoured for analysis over one comprising 'no treatment'.
Outcome Definitions
For each trial, and for the purposes of risk-of-bias assessment, we identified a 'main outcome measure' using a refinement of the approaches adopted by Linde et al and by Shang et al. 15, 16 As for our previous SRs, 2-4 and per protocol, 11 each trial's 'main outcome measure' was identified based on a hierarchical ranking order (consistent with the WHO ICF Classification System for Levels of Functioning Linked to Health Condition b ).
We followed the WHO ICF system without reference to any 'primary outcome measure' that might have been identified by the original investigators. Unless otherwise indicated, the single end-point (measured from the start of the intervention) associated with our designated 'main outcome measure' was taken as the last follow-up at which data were reported for that outcome.
Data Extraction
Two assessors (RTM and YYYF, or RTM and PV) independently extracted relevant data using a standard data recording approach, in spreadsheet format (Microsoft Excel). The data extracted per trial included, as appropriate: demographics of participants (gender, age range, clinical condition); study setting; potency or potencies of homeopathic medicines; dosage frequency; whether a pilot trial; 'main outcome measure' (see below) and measured end-point; other outcome measures reported; funding source/s. The statistical items noted were: sample size and missing data for each intervention group; whether power calculation carried out; whether intention-to-treat (ITT), per-protocol, complier-average-causal-effect, 17 or other type of primary analysis.
Assessment of Risk of Bias (Internal Validity)
Using the standard criteria defined by Cochrane, 14 the extraction of information enabled appraisal of 'low risk', 'uncertain risk' or 'high risk' of bias with respect to: (domain I) the methods used to generate the random sequence; (domain II) the method of allocation concealment used to implement the random sequence; (domain IIIa) the blinding of participants and/or study personnel; (domain IIIb) the blinding of outcome assessors; (domain IV) completeness of the outcome data included in the analysis; (domain V) evidence of selective outcome reporting; (domain VI) evidence of other bias, including data imbalance between the groups at baseline. Two or three assessors (RTM and PV, or RTM and YYYF and AKLT) carried out their assessments independently, with discrepancies between them resolved by consensus discussion and, if necessary, the input of another co-author. For domain IV, a trial was normally regarded as no better than 'unclear' if there was greater than 20% participant attrition rate, irrespective of whether ITT analysis had been carried out. Domain V was automatically attributed 'high risk of bias' if its designated main outcome measure could not be extracted to enable calculation of 'relative effect size' (see below). The nature of any research sponsorship was taken into account for sub-group analysis (see below), not in riskof-bias assessment per se.
Rating of Trials for Risk of Bias
As per the standard Cochrane approach, each trial was designated: low risk of bias for all key domains; or uncertain risk of bias for one or more key domains; or high risk of bias for one or more key domains.
14 We used our novel method of nomenclature, based on the Cochrane approach, for rating risk-of-bias characteristics across all domains per trial: 
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of bias was for one of domains IV, V or VI only (i.e. it is required to be judged free of bias for each of domains I, II, IIIa and IIIb).
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It is expected that an OTP-controlled trial would be rated 'high risk of bias' in assessment domain IIIa. We recognise that this is a normal feature of an OTP-controlled trial, and which thus inevitably limits its internal validity-see also the section Sensitivity Analyses, below.
Assessment of Pragmatic/Explanatory Attitude (External Validity)
Equating external validity to study attitude, we adopted the PRECIS approach 10 to assess each trial's positioning on the pragmatic-explanatory continuum, taking account of 10 domains: Discrepancies between assessments (per attribute and by overall characterisation per trial) were resolved by consensus discussion. Initial attention focused on each domain for which the two independent scores were a value of 2 or more apart, and with the aim of narrowing the discrepancy to no more than a value of 1. Subsequent discussion aimed to reappraise any studies whose two sets of total scores lay on either side of a threshold for overall characterisation of pragmatic/explanatory attitude, with a view to agreeing a final designation; we did not aim to calculate the mean value of the two independent total PRECIS scores.
Study Selection for Meta-Analysis
All RCTs that were included in the SR were potentially eligible for meta-analysis. If the original article did not provide or inform adequate data on the selected 'main outcome measure' to enable extraction or calculation of the standardised mean difference (SMD) or the odds ratio (OR), we described the selected main outcome as 'not estimable': an alternative, estimable, outcome was not sought.
Consistent with the above, the following studies were excluded from meta-analysis:
• Those that presented non-parametric data only, and where there was no information that enabled the data distribution to be assessed; • Those from which the necessary data could not be extracted (not provided or uninterpretable).
Summary Measures for 'Main Outcome'
For the remaining relevant records of NIHT, we aimed to examine (1) overall relative effect sizes; (2) relative effect sizes by disease; (3) relative effect sizes by disease category.
In each of these three cases, 'relative effect size' was taken as the difference (if relevant-see below) between the homeopathy and the control groups at the identified end-point of the trial, and using per-protocol data: In trials where the main outcome measure was a continuous variable, and where there were insufficient data presented to identify the mean and/or the standard deviation (SD) per group at the defined end-point, the necessary data were estimated, if possible, by imputing relevant other data from the same study.
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Statistical Interpretation per Study Design
The interpretation of a statistical finding of p < 0.05 (direction of effect towards homeopathy or towards control) and of p > 0.05 (direction of effect towards either homeopathy or control) has been detailed in our recent SR of OTP-controlled trials of individualised homeopathic treatment.
2 We separately interpreted the findings from 'equivalence' or 'noninferiority' trials, 19, 20 reflecting the original authors' margin of equivalence or non-inferiority as appropriate. For any RCT or group of RCTs on a given clinical condition/ category, the interpretation of NIHT as 'effective', 'ineffective' or 'inconclusive' applied solely to the particular clinical condition/category examined.
Synthesis of Quantitative Results
Overall 'Relative Effect Size' of NIHT For groups of eligible RCTs that have compared NIHT (1a) with another intervention, or (1b) adjunctively with another intervention, or (2) with no treatment, we aimed to pool for c OR > 1 favours homeopathy. d SMD < 0 favours homeopathy. meta-analysis the 'main outcome' data in two separate sets of studies as appropriate, using either the OR or the SMD of each relevant trial. 21 For each study design (1a, 1b, 2), it was then planned to combine data-if sufficient in number-from the two sets of studies (OR and SMD) into a single forest plot, re-expressing SMDs by transformation to OR, using an approximation method proposed by Chinn 22 and recommended by the Cochrane Statistical Methods Group.
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Based on the assumption of at least moderate clinical heterogeneity among studies, the 'random effects' statistical model for meta-analysis was selected rather than the 'fixed effect' model.
21
Disease-and Category-Specific 'Relative Effect Size' of NIHT For each specific clinical condition or category of conditions, for each of study designs 1a, 1b and 2, and for which there was >1 RCT of given type and with extractable main outcome, we planned to pool the data using meta-analysis.
Heterogeneity and Asymmetry
The I 2 statistic was used to assess the variability between studies in a given meta-analysis: it gives the percentage of the total variability in the estimated effect size (which is composed of between-study heterogeneity plus sampling variability) that is attributable to heterogeneity. The I 2 statistic can take values between 0% and 100%:
means that all of the heterogeneity is due to sampling error; I 2 ¼ 100% means that all variability is due to true heterogeneity between studies. Where feasible, it was intended to use funnel plots to assess the impact of publication bias.
Additional Quantitative Analyses on Overall 'Relative Effect Size' of NIHT
Sensitivity Analyses
We planned sensitivity analyses based separately on (1) our risk-of-bias ratings and on (2) our assessments of external validity. We aimed to reflect in this analysis any trial that was categorised as '(much) more pragmatic than explanatory' and whose internal validity was compromised by high risk of bias in domain IIIa only (blinding of participants and/or study personnel).
Sub-Group Analyses
Comparative forest plots were planned-for each of study designs 1a, 1b and 2-on the following sub-groups of trial attributes:
• Whether or not a pilot (or 'preliminary' or 'feasibility') study, as defined by the original authors; • Whether or not sample size > median for all trials with extractable data; • Whether or not potency/potencies of homeopathic medicines !12C; • Whether or not the research sponsor is an organisation (e.g. homeopathic pharmacy) with potential vested interest in the trial findings.
Results
Included Studies
The PRISMA flowchart from the original comprehensive literature search (up to and including 2011) was published previously. 12 An updated PRISMA flowchart is given in ►Fig. 
Characteristics of Included Studies
The 17 RCTs represented 15 clinical conditions across 13 categories (►Table 1). Homeopathic potency was !12C in three of the 15 trials for which relevant information was available. Five trials were free of vested interest; five trials were not free of vested interest; seven trials did not enable certainty in this assessment.
Summary of Findings
For each trial, ►Table 2 includes details of the sample size, the identified main outcome measure (and whether dichotomous or continuous), the end-point, and a number of other study attributes. Two trials were described in the original article as a 'pilot' (or 'preliminary' or 'feasibility') study. A power calculation was carried out for eight of the trials. ITT was the basis for the original analysis in four trials. Mean attrition rate per RCT was 7.4%. The main outcome variable was dichotomous in four studies and continuous in the other 13. Only 6 of the 17 original RCTs clearly described a 'main' or 'primary' outcome (A153, Karow; A159, Taylor; A163, Weiser; A297, Mourão; A304, Thinesse-Mallwitz; A319, Jong); in each of the 6 cases, this corresponded to our designated 'main outcome measure'. The total sample size was 1,376 for the 10 trials whose data were amenable to quantitative analysis; their median sample size was 102 (inter-quartile range: 56.5 to 144.5). The 10 analysable studies included 10 different main outcome measures and for an end-point that ranged from 4 days to 2 years. Other-than-Placebo-Controlled RCTs of Non-Individualised Homeopathy Mathie et al.
Risk of Bias
domain IIIb (blinding of outcome assessors) and domain V (selective outcome reporting) presented the greatest methodological concerns. The seven trials with high risk of bias for domain V were so because they did not contain data that were extractable for meta-analysis. Domain I (sequence generation) and domain II (allocation concealment) presented the most uncertain methodological judgments. There were no A-or B1 Ã -rated trials. Three trials (A151, Issing; A162, Weiser; A163, Weiser) were rated uncertain risk of bias ('B1'-or 'B2'-rated). Fourteen trials were assessed as high risk of bias ('C'-rated); one of those (A297, Mourão) was judged high risk of bias for domain IIIa only. Seven 'C'-rated trials were deficient in two or more domains of assessment ('C2.0'-rated or worse). A summary risk-of-bias bar-graph is shown in ►Supplementary File 3 (online only).
Pragmatic/Explanatory Attitude
Independent assessment identified a total of 52 domains (2 to 6 domains per trial) for which the two scores were ! 2 apart. In all cases, consensus discussion narrowed the score discrepancy per domain to no more than 1, which was our target. There were two trials for which the consequent two total scores lay on either side of a threshold for overall characterisation of pragmatic/explanatory attitude: however, a final designation per trial was readily achieved through further consensus discussion (►Table 3).
Three of the trials were more pragmatic than explanatory, 2 were more explanatory than pragmatic, and 12 were equally pragmatic and explanatory. One of the three trials categorised as 'more pragmatic than explanatory' (A287, Villanueva) had high risk of bias in domain IIIa only (blinding of participants and/or study personnel).
Across all trials, each of 47 domains was given a score of 3 by both assessors due to the absence of sufficient information in the original article: this lack of information pertained especially to domains 3 (practitioner expertise-homeopathy), 5 (practitioner expertise-comparison intervention), 8 (participant compliance) and 9 (protocol adherence).
Meta-Analysis
The selected main outcome was 'not estimable' for seven studies (►Supplementary File 2 [online only]), for which group SDs for the designated end-point could not be derived, or for which only non-parametric analysis was given. For the Other-than-Placebo-Controlled RCTs of Non-Individualised Homeopathy Mathie et al. Other-than-Placebo-Controlled RCTs of Non-Individualised Homeopathy Mathie et al.
remaining 10 studies, 6 were in study-design category 1a (other-intervention control) and 4 were in category 1b ('[A þ B] versus B'); there were no trials in category 2 (notreatment control). Three category 1a studies with extractable data were either equivalence or non-inferiority trials and were examined as a separate group.
Overall Relative Effect Sizes
Study Design 1a: Other-Intervention Control
Given merely three superiority trials of study design 1a with extractable quantitative data, and also with manifest diversity of clinical conditions (common cold and leprosy) and measured end-points (4 days to 2 years), it was deemed inappropriate to merge OR and SMD data for these studies. Individually, each of two of the trials (A150, Gassinger; A155, Maiwald) had a non-significant effect favouring homeopathy; the third trial (A305, Chakraborty) had a statistically significant effect favouring homeopathy (►Table 4), though the very large effect size (OR, 695) was evidently an extreme outlier.
As was shown in ►Table 3, each of the three trials displayed high risk of bias. Two trials (A150, Gassinger; A155, Maiwald) were equally pragmatic and explanatory in attitude; the third trial (A305, Chakraborty) was more pragmatic than explanatory. This small number of low-quality trials did not justify our intended sensitivity analyses or our planned sub-group analyses.
Equivalence and Non-Inferiority Trials
Individually, one of the three trials (A151, Issing, which studied vertigo) had a non-significant effect favouring homeopathy; each of the other two trials (A162, Weiser [vertigo] ; A163, Weiser [seasonal allergic rhinitis]) had a non-significant effect favouring control (►Table 4).
The pooled effect estimate for these three trials was SMD ¼ 0.08 (95% CI: -0.13 to 0.28; p ¼ 0.46)-see ►Fig. 2. Collectively, the trials are clinically heterogeneous (two studies on vertigo and one on seasonal allergic rhinitis) but were statistically non-heterogeneous. Each of the trials displayed uncertain risk of bias and a study attitude that was equally pragmatic and explanatory (►Table 3).
Due to the close similarity of trial attributes and the small number of the studies, it was deemed inappropriate to conduct sensitivity analysis or sub-group analysis. 
Study Design 1b: '[A þ B] versus B'
There were four trials in this category: two with dichotomous data, and two with continuous data, all of which were extractable for analysis. With merely four trials in total, it was inappropriate to merge OR and SMD data for these studies.
Individually, three of the four trials (A287, Villanueva; A297, Mourão; A304, Thinesse-Mallwitz) had a significant effect favouring homeopathy; the other trial (A159, Taylor) had a non-significant effect favouring control (►Table 4).
For the two trials with dichotomous data (A287, Villanueva; A304, Thinesse-Mallwitz), the pooled effect estimate extreme heterogeneity (►Fig. 4). These two studies also displayed marked clinical heterogeneity (acute otitis media and chronic periodontitis respectively).
As was shown in ►Table 3, each of the four 1b-design trials displayed high risk of bias. The study attitudes of these trials were a mix of pragmatic and explanatory. One of the RCTs (A287, Villanueva), which was more pragmatic than explanatory, had high risk of bias in domain IIIa only: a sensitivity analysis (which we have not undertaken) would have taken that factor into account. For the same reason as for the 1a trials above, we did not undertake sensitivity or sub-group analyses.
Disease-and Category-Specific Relative Effect Sizes
Despite the overall diversity of clinical conditions and categories of condition, there were two trials that focused on common cold and shared the same study design (A150, Gassinger; A155, Maiwald). The study medicine in each case comprised Eupatorium perfoliatum; the comparator in each case was acetylsalicylic acid. Merging the OR and the SMD data for these studies, OR ¼ 1.54 (95% CI: 0.81 to 2.93; p ¼ 0.19)-►Fig. 5. Each study has high risk of bias; each is equally pragmatic and explanatory.
Discussion
None of the 17 studies was judged to comprise reliable evidence (i.e. there were no A-or B1 Ã -rated trials), 14 being assessed as high risk of bias. Seven of the 17 articles failed to yield data suitable for meta-analysis, leaving a total of 10 studies in different categories of study design. Because of their diverse clinical nature and outcome measures-as well as their small number-it was deemed inappropriate to conduct meta-analysis on the three superiority trials of study design 1a. For the equivalence and non-inferiority trials collectively, the small, non-significant, effect size observed in meta-analysis (SMD ¼ 0.08; p ¼ 0.46) was consistent with a conclusion that NIHT did not differ from treatment by a comparator (Ginkgo biloba or betahistine) for vertigo or (cromolyn sodium) for seasonal allergic rhinitis. For four studies of design 1b, any significant effect favouring adjunctive NIHT was mitigated by their extreme heterogeneity. The overall low intrinsic quality and number of studies add further caution in trying to reach any Lack of replication of subject matter allowed just one meta-analysis by clinical condition: pooling data from two 'C'-rated trials of common cold, where NIHT comprised Eupatorium perfoliatum in each case, found no difference in treatment effect compared to that of aspirin (OR ¼ 1.54; p ¼ 0.19). It is thus inconclusive whether Eupatorium and acetylsalicylic acid (aspirin) differ in effectiveness for treating common cold symptoms.
Within the pragmatic-explanatory continuum, the internal validity for pragmatic study design would naturally be lower than that for explanatory design. 8 Logically, therefore, an intrinsically low-quality study might be expected to have more emphasis placed on external validity; however, it is notable that, despite their OTP-controlled design, only three of the studies possessed a truly pragmatic study attitude. The external validity of 14 trials was, therefore, little or no higher than that of an overtly explanatory trial, with limited generalisability of findings to a wider population of patients.
Being equally pragmatic and explanatory in attitude, the equivalence and non-inferiority trials of NIHT (A151, Issing; A162, Weiser; A163, Weiser) were found to lack clear external validity; moreover, their overall risk of bias in each case was uncertain ('B1'-or 'B2'-rated) rather than high. Amongst the studies that examined adjunctive homeopathy, just one (A287, Villanueva) of the four was more pragmatic than explanatory in attitude. The latter was the solitary example of a trial with high risk of bias in domain IIIa only, preventing our intended sensitivity analysis on this point. We have previously commented on the rigour of the Cochrane approach in this respect.
2
Although the PRECIS tool was originally developed to help at the design stage of clinical trials, 10 we found it fairly straightforward to apply in assessing the pragmatic/explanatory attitude of a completed study. The scoring notation we implemented proved able to approximate a given trial's positioning on the pragmatic-explanatory continuum, with little difficulty in reconciling inter-rater assessments. The 10-domain judgmental criteria were operationalised successfully, though there was often a lack of information in the published articles to form a clear opinion on the following: practitioner expertise in homeopathy (domain 3); practitioner expertise in the comparison intervention (domain 5); participant compliance (domain 8); protocol adherence (domain 9).
Conclusion
It is currently not possible to form a decisive conclusion regarding comparative effectiveness of NIHT on healthrelated outcomes, assessed within the context of OTP-controlled trials. Generalisability of findings is limited by the very small number of studies that have predominantly pragmatic attitude. Amongst NIHT studies currently, the highest intrinsic quality is seen in those designed as an equivalence or non-inferiority trial. Mirroring the conclusion of our recent SR, 2 future OTP-controlled trials in NIHT should aim, as far as possible, to promote both internal validity and external validity.
Highlights
• This systematic review focuses on randomised controlled trials (RCTs) of non-individualised homeopathic treatment (NIHT) in which the control (comparator) group was other than placebo.
• For each eligible trial, risk of bias was assessed using Cochrane methods, and its relative pragmatic or explanatory attitude was approximated using the PRECIS tool.
• Seventeen RCTs, representing 15 different medical conditions, were eligible for inclusion.
• Fourteen RCTs were rated 'high risk of bias'; the other three trials were rated 'uncertain risk of bias'.
• Only three RCTs were judged to have clearly pragmatic study attitude.
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